Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Brokerages

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $17.00.

A number of research firms have recently commented on OCUL. Scotiabank began coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd.

Ocular Therapeutix Stock Performance

Shares of OCUL traded up $0.03 during midday trading on Monday, reaching $7.48. 915,529 shares of the stock were exchanged, compared to its average volume of 925,984. The business's 50-day moving average price is $8.35 and its 200 day moving average price is $8.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix has a twelve month low of $4.06 and a twelve month high of $11.77. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -5.67 and a beta of 1.22.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Donald Notman sold 6,301 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $7.84, for a total transaction of $49,399.84. Following the transaction, the insider now owns 204,563 shares in the company, valued at approximately $1,603,773.92. The trade was a 2.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jeffrey S. Heier sold 2,948 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now owns 269,059 shares in the company, valued at $2,424,221.59. The trade was a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,368 shares of company stock worth $162,801 in the last quarter. Company insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors and hedge funds have recently added to or reduced their stakes in OCUL. Atlas Capital Advisors Inc. purchased a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 1,015 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $53,000. Capital Performance Advisors LLP purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter worth approximately $70,000. Finally, Walleye Capital LLC purchased a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $90,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.